1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,254 | 1,312 | 21.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| AELIS FARMA Aktie jetzt für 0€ handeln | |||||
| 07.04. | Aelis Farma erhält 458.000 Euro für Adipositas-Forschung | 2 | Investing.com Deutsch | ||
| 07.04. | Aelis Farma receives €458,000 grant for obesity research | 1 | Investing.com | ||
| 07.04. | Aelis Farma Awarded a €458k Grant Under France 2030 in Nouvelle-Aquitaine to Support Development of Its Program in Obesity and Associated Metabolic Diseases | 262 | Business Wire | This non-dilutive funding, granted under the Projets d'Avenir Innovation (PAI) scheme, strengthens Aelis Farma's "metabolism" program and validates its innovation potential in a therapeutic area... ► Artikel lesen | |
| 30.03. | Aelis Farma Reports Its 2025 Annual Financial Results and Confirms Its 2026 Outlook | 550 | Business Wire | 2025 has been marked by several significant events: The achievement of key milestones for the Company's two drug candidates:
AEF0117: announcement of the final results of the Phase... ► Artikel lesen | |
| 21.03. | Aelis Farma startet Patientenrekrutierung für Studie zu Down-Syndrom-Medikament | 2 | Investing.com Deutsch | ||
| 21.03. | Aelis Farma begins recruiting for Down syndrome drug trial | 2 | Investing.com | ||
| 21.03. | Aelis Farma announces the successful start of the recruitment of the Phase 2B clinical trial with AEF0217 for the treatment of behavioral and cognitive impairments of people with Down syndrome (Trisomy 21) | 712 | Business Wire | AEF0217 is a first-in-class Signalling Specific inhibitor of the CB1 receptor (CB1-SSi) developed as a treatment for impairments in adaptive behaviours and cognition in neurodevelopmental disorders... ► Artikel lesen | |
| 26.01. | Aelis Farma Announces Its 2026 Financial Calendar | 266 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral... ► Artikel lesen | |
| 12.01. | Aelis Farma Receives a Positive Opinion From EMA Pediatric Committee on the Pediatric Investigation Plan for AEF0217 in Down Syndrome | 329 | Business Wire | The EMA's Pediatric Committee (PDCO) has delivered a favorable consensus opinion on the Pediatric Investigational Plan (PIP) of Aelis Farma's first-in-class drug candidate AEF0217 for the treatment... ► Artikel lesen | |
| 02.12.25 | Aelis Farma Obtains Regulatory Approval of the Phase 2B Trial With AEF0217 in People With Down Syndrome | 440 | Business Wire | AEF0217 is a first-in-class CB1 receptor Signalling Specific inhibitor (CB1-SSi) developed as a potential first pharmacological treatment for impairments in adaptive behaviours and cognition... ► Artikel lesen | |
| 25.09.25 | Aelis Farma: Availability of the 2025 Half-Year Financial Report | 396 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specialising in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 22.09.25 | Aelis Farma Reports 2025 Half-Year Financial Results and Presents Progress and Development Outlook | 566 | Business Wire | The first half of 2025 was marked by: The publication of the final analysis of the pioneering Phase 2b clinical trial in cannabis use disorders (CUD) with the CB1-SSi AEF0117, which further... ► Artikel lesen | |
| 24.06.25 | Aelis Farma: Availability of the Description of the Share Buyback Program | 439 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 27.05.25 | Results of Aelis Farma Combined General Meeting of May 27, 2025 | 473 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 06.05.25 | Aelis Farma: Combined General Meeting of May 27, 2025: Availability of Preparatory Documents and Participation and Voting Procedures | 478 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 29.04.25 | Aelis Farma: Availability of the 2024 Universal Registration Document | 396 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 34,700 | -0,72 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| BIONTECH | 95,00 | +6,62 % | Mesoblast: Wenn aus Vision plötzlich Umsatz wird | ||
| SUMMIT THERAPEUTICS | 26,380 | +5,02 % | UBS reiterates Buy on Summit Therapeutics stock ahead of trial data | ||
| EVOTEC | 5,650 | +0,18 % | Aktie "falsch bewertet": Wie Evotec am KI-Boom verdient | KI macht Arzneimittelforschung billiger - und schafft paradoxerweise mehr Arbeit für Evotec. Warum Berenberg die Aktie trotz operativer Schwäche klar zum Kauf empfiehlt. Die Pharmaindustrie setzt zunehmend... ► Artikel lesen | |
| MODERNA | 45,925 | -0,85 % | Moderna - MRNA: Impfstoff-Aktie mit mega-starkem Comeback! | + 100 Prozent in 6 Monaten! mrRNA-Impfstoffe gegen Krebs, Grippe & RSV bei Moderna in der Pipeline! Neue Rallye trotz US-Gesundheitsminister Robert F. Kennedy? Moderna (MRNA) - ISIN US60770K1079 Rückblick:... ► Artikel lesen | |
| ERASCA | 22,445 | +3,43 % | Erasca, Inc. - 8-K, Current Report | ||
| HARMONY BIOSCIENCES | 32,210 | +9,08 % | Dravet-Syndrom: Harmony Biosciences präsentiert neue Studiendaten | ||
| DAY ONE BIOPHARMACEUTICALS | 21,485 | 0,00 % | Day One Biopharmaceuticals, Inc. - 10-K/A, Annual Report | ||
| NUVALENT | 107,06 | -1,12 % | Nuvalent presents zidesamtinib data in pre-treated lung cancer | ||
| ADMA BIOLOGICS | 10,790 | -0,92 % | Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns? | ||
| RECURSION PHARMACEUTICALS | 3,555 | -3,40 % | Why Recursion Pharmaceuticals Inc (RXRX) Expanded Citeline Partnership | ||
| PSYENCE BIOMEDICAL | 9,820 | -12,40 % | Psyence Biomedical Ltd.: Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine | NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin... ► Artikel lesen | |
| SPRUCE BIOSCIENCES | 51,45 | -25,67 % | Morning Market Movers: Local Bounti, Click Holdings, SciSparc, Spruce Biosciences See Big Swings | BEIJING (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,790 | +5,34 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat | - Matthew Gall appointed Chief Financial Officer -- Additional key appointments add expertise in clinical operations, corporate strategy and project leadership - BOSTON, April 15, 2026 (GLOBE... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 341,38 | -0,19 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen |
Das Unternehmen AELIS FARMA SAS kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,256 Euro und damit +2,28 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AELIS FARMA SAS finden Sie auf Wallstreet Online.